Published : 7 September, 2026
Dr. Pankaj Goyal, Senior Consultant & Unit Head – Medical Oncology at RGCIRC, featured in News18, discussing India’s emerging “smart” cancer drug RK-251 and its potential to target cancer cells while limiting damage to healthy tissue. The article explains that although the drug shows promise, it is still in the preclinical stage and cannot currently replace chemotherapy, with human clinical trials still required. Dr. Goyal’s inputs highlight the importance of evidence from clinical studies before such targeted therapies can be considered safe and effective alternatives to established cancer treatments.
My Reports
RGCIRC, Niti Bagh
